Gamma Biosciences is a leading life sciences company providing products and services to support the development and manufacturing of advanced biologic therapies. Our operating companies are committed to advancing the science and art of bioprocessing by delivering market-ready innovation and expertise that helps our customers, mainly biopharmaceutical companies and contract development and manufacturing companies, safely bring therapies to patients more quickly and efficiently. Gamma is a global company with offices and major manufacturing facilities in North America, the U.K. and Belgium.

The Team

President

Matt Gunnison

Chief Technology Officer

Phil Vanek, PhD

Vice President

Eric Simpson

Matt oversees the Gamma portfolio and is responsible for identifying and executing investments as well as driving growth, strategic and operational initiatives and business development activities at Gamma’s portfolio companies. Matt was most recently Global Head of Business Development for GE Healthcare, where he was responsible for M&A and strategic alliances across the $19B division of GE. Matt joined GE in 2011 and held a variety of other leadership positions in strategy, business development, venture investing and new business creation during his nearly nine years at the company. Matt began his career as a corporate attorney at Sidley Austin LLP. He holds a J.D. from the University of Michigan and a B.A. in Economics from Georgetown University.

Phil is responsible for technical due diligence and evaluation of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. An entrepreneurial and strategic international business leader, Phil joins Gamma from GE Healthcare’s Cell and Gene Therapy business unit where he directed strategy and portfolio growth. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center followed by an IRTA fellowship at the National Cancer Institute in Maryland, and at the Hollings Cancer Center in Charleston, SC. Phil was an instructor for Johns Hopkins University Advanced Academic Programs teaching Biotechnology Marketing in the Masters of Biotechnology / MBA program, and has held leadership positions in a number of life sciences companies including Life Technologies, Becton Dickinson, and Lonza. Phil is a Board Member of CCRM in Toronto Canada and a Board Member of the ARM Foundation.

Eric focuses on financial diligence and deal execution for new investments, and ongoing portfolio management. Prior to joining Gamma Eric led product management for Zymergen, a biomanufacturing company, where he oversaw technology development for new capabilities including bioinformatics and data science. Eric began his career as a consultant with Bain & Company, advising on technology strategy and M&A due diligence. He holds a B.S. in Materials Science Engineering and Economics from Northwestern University and an MBA from Harvard Business School.

Eric focuses on financial diligence and deal execution for new investments, and ongoing portfolio management. Prior to joining Gamma Eric led product management for Zymergen, a biomanufacturing company, where he oversaw technology development for new capabilities including bioinformatics and data science. Eric began his career as a consultant with Bain & Company, advising on technology strategy and M&A due diligence. He holds a B.S. in Materials Science Engineering and Economics from Northwestern University and an MBA from Harvard Business School.

Matt oversees the Gamma portfolio and is responsible for identifying and executing investments as well as driving growth, strategic and operational initiatives and business development activities at Gamma’s portfolio companies. Matt was most recently Global Head of Business Development for GE Healthcare, where he was responsible for M&A and strategic alliances across the $19B division of GE. Matt joined GE in 2011 and held a variety of other leadership positions in strategy, business development, venture investing and new business creation during his nearly nine years at the company. Matt began his career as a corporate attorney at Sidley Austin LLP. He holds a J.D. from the University of Michigan and a B.A. in Economics from Georgetown University.

Phil is responsible for technical due diligence and evaluation of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. An entrepreneurial and strategic international business leader, Phil joins Gamma from GE Healthcare’s Cell and Gene Therapy business unit where he directed strategy and portfolio growth. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center followed by an IRTA fellowship at the National Cancer Institute in Maryland, and at the Hollings Cancer Center in Charleston, SC. Phil was an instructor for Johns Hopkins University Advanced Academic Programs teaching Biotechnology Marketing in the Masters of Biotechnology / MBA program, and has held leadership positions in a number of life sciences companies including Life Technologies, Becton Dickinson, and Lonza. Phil is a Board Member of CCRM in Toronto Canada and a Board Member of the ARM Foundation.

Eric focuses on financial diligence and deal execution for new investments, and ongoing portfolio management. Prior to joining Gamma Eric led product management for Zymergen, a biomanufacturing company, where he oversaw technology development for new capabilities including bioinformatics and data science. Eric began his career as a consultant with Bain & Company, advising on technology strategy and M&A due diligence. He holds a B.S. in Materials Science Engineering and Economics from Northwestern University and an MBA from Harvard Business School.